Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Dréanic, Johann ^a   Maillet, Marianne ^a   Dhooge, Marion ^a   Mir, Olivier ^a   Brezault, Catherine ^a   Goldwasser, François ^a   Chaussade, Stanislas ^a   Coriat, Romain ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Cetuximab; Chemotherapy; Colorectal cancer; Glasgow Prognostic Score; Performance status

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ALBUMINOID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; C REACTIVE PROTEIN; CAMPTOTHECIN; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; KIDNEY FUNCTION; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; AGED; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; GLASGOW OUTCOME SCALE; METABOLISM; PATHOLOGY; PROGNOSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS;

AGED; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GLASGOW OUTCOME SCALE; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84879766570     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0656-y     Document Type: Article

References (13)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29. doi:10.3322/caac.20138.
2. Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):61-3. doi:10.1093/annonc/mdp130.
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360 (14):1408-17. doi:10.1056/NEJMoa0805019.
4. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6): 649-55.
5. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced nonsmall cell lung cancer. Br J Cancer. 2001;85(11):1634-9. doi:10.1054/bjoc.2001.2162.
6. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704-6. doi:10.1038/sj.bjc. 6601789.
7. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010;103(6):870-6. doi: 10.1038/sj.bjc.6605855.
8. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007; 246(6):1047-51. doi:10.1097/SLA. 0b013e318145417100000658-200712000-00019.
9. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104 (4):726-34. doi:10.1038/sj.bjc.6606087.
10. Hashiguchi Y, Hase K, Kotake K, Ueno H, Shinto E, Mochizuki H, et al. Evaluation of the seventh edition of the tumour, node, metastasis (TNM) classification for colon cancer in two nationwide registries of the United States and Japan. Colorectal Dis. 2012;14(9):1065-74. doi:10.1111/j.1463-1318. 2011.02917.x.
11. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7(5):331-7. doi:10.3816/CCC. 2008.n.044.
12. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-40. doi:10.1016/j.ctrv.2012. 08.003.
13. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer. 1998;31(2):101-5. doi:10.1080/01635589809514687.